clinical trial · NCT03701490
Prolutex in Frozen Embryo Transfer Cycles At the Blastocyst Stage (PROGEX)
InfertilityProgesterone subcutaneousProgesterone Vaginal Product
brief summary
The objective of this proof of concept clinical trial is to evaluate the impact of two different progesterone treatments for endometrial preparation (25 mg/twice-a-day, subcutaneous injection, and 200 mg/three times a day, vaginal administration) on the clinical pregnancy rate in women undergoing frozen embryo transfer (FET) at blastocyst stage.
started
Mar 12, 2019
primary completion
Sep 28, 2022
completion
Dec 3, 2022
last updated
Nov 22, 2024
official title
A Proof of Concept, Randomized, Controlled Clinical Trial to Assess the Efficacy of Subcutaneous Progesterone (Prolutex) Versus Vaginal Progesterone (Progeffik) for Endometrial Preparation in Women Undergoing Frozen Embryo Transfer(FET) Cycles
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol